TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | -101.86%-51.93M | ---- | 229.15%2.79B | ---- | -167.18%-2.16B | ---- | 25.18%-809.56M | ---- | -64.33%-1.08B |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | -499.10%-86.85M | ---- | -245.97%-14.5M | ---- | -108.67%-4.19M | ---- | 59.34%-2.01M | ---- | 58.37%-4.94M |
Attributable subsidiary (profit) loss | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -61.00%18.92M |
Impairment and provisions: | ---- | -193.69%-135.29M | ---- | -83.67%144.39M | ---- | 297.70%884.46M | ---- | 116.61%222.39M | ---- | -19.14%102.67M |
-Impairment of property, plant and equipment (reversal) | ---- | 189.49%136.53M | ---- | -93.17%47.16M | ---- | 1,757.55%690.94M | ---- | --37.2M | ---- | ---- |
-Other impairments and provisions | ---- | -379.57%-271.82M | ---- | -49.76%97.23M | ---- | 4.50%193.52M | ---- | 80.38%185.2M | ---- | 80.24%102.67M |
Revaluation surplus: | ---- | -49.21%154.06M | ---- | 19.52%303.32M | ---- | 490.81%253.78M | ---- | 241.99%42.95M | ---- | 836.66%12.56M |
-Fair value of investment properties (increase) | ---- | -49.21%154.06M | ---- | 19.52%303.32M | ---- | 490.81%253.78M | ---- | 241.99%42.95M | ---- | 836.66%12.56M |
Asset sale loss (gain): | ---- | 99.95%-1.99M | ---- | -4,686.82%-4.22B | ---- | -226,089.74%-88.14M | ---- | -79.26%39K | ---- | 100.95%188K |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---4.22B | ---- | ---- | ---- | ---- | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | 138.04%124K | ---- | -46.19%-326K | ---- | -671.79%-223K | ---- | -79.26%39K | ---- | -84.53%188K |
-Loss (gain) from selling other assets | ---- | ---2.11M | ---- | ---- | ---- | ---87.91M | ---- | ---- | ---- | ---- |
Depreciation and amortization: | ---- | -9.48%49.31M | ---- | -21.05%54.48M | ---- | 17.07%69M | ---- | 7.48%58.94M | ---- | -0.87%54.83M |
Financial expense | ---- | -75.41%239.93M | ---- | -2.58%975.71M | ---- | 25.21%1B | ---- | 3.74%799.9M | ---- | -4.23%771.03M |
Exchange Loss (gain) | ---- | 2,573.70%23.7M | ---- | -106.47%-958K | ---- | 57.12%-464K | ---- | 49.01%-1.08M | ---- | 89.70%-2.12M |
Special items | ---- | 305.79%1.71M | ---- | ---829K | ---- | ---- | ---- | ---1.09M | ---- | ---- |
Operating profit before the change of operating capital | ---- | 431.34%192.66M | ---- | 177.08%36.26M | ---- | -115.15%-47.04M | ---- | 340.81%310.48M | ---- | -133.69%-128.93M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | -94.97%39K | ---- | 6,954.55%776K | ---- | -98.09%11K | ---- | 38.13%576K | ---- | 151.23%417K |
Developing property (increase)decrease | ---- | ---- | ---- | -163.79%-108.24M | ---- | -94.20%169.67M | ---- | 11,463.92%2.93B | ---- | -100.85%-25.74M |
Accounts receivable (increase)decrease | ---- | 151.38%63.57M | ---- | -1,550.82%-123.73M | ---- | --8.53M | ---- | ---- | ---- | 216.83%224.29M |
Accounts payable increase (decrease) | ---- | -108.98%-1.33M | ---- | -78.80%14.76M | ---- | --69.62M | ---- | ---- | ---- | ---- |
prepayments (increase)decrease | ---- | ---- | ---- | ---- | ---- | 112.52%384K | ---- | -134.09%-3.07M | ---- | 346.72%8.99M |
Special items for working capital changes | ---- | ---- | ---- | ---- | ---- | 101.88%44.7M | ---- | -348.23%-2.37B | ---- | 153.76%956.06M |
Cash from business operations | -66.04%91.23M | 241.50%254.94M | 207.20%268.64M | -173.28%-180.17M | -447.41%-250.59M | -71.40%245.87M | -86.78%72.13M | -16.93%859.83M | 104.85%545.46M | -65.04%1.04B |
Other taxs | ---- | 30.56%10.33M | 160.75%10.56M | -34.52%7.91M | 72.95%-17.39M | 108.29%12.08M | 37.64%-64.27M | 29.75%-145.6M | 37.18%-103.06M | 67.83%-207.25M |
Interest received - operating | 15.00%851K | -92.38%1.11M | -94.93%740K | 245.97%14.5M | 331.49%14.61M | 108.67%4.19M | 106.40%3.39M | -59.34%2.01M | -52.90%1.64M | -58.37%4.94M |
Interest paid - operating | 71.00%-74.55M | -22.87%-148.74M | -218.17%-257.11M | 53.28%-121.05M | 37.85%-80.81M | 34.75%-259.08M | 51.16%-130.03M | 48.16%-397.04M | 33.88%-266.24M | 23.22%-765.93M |
Net cash from operations | -23.22%17.53M | 142.19%117.63M | 106.83%22.83M | -9,226.58%-278.82M | -181.33%-334.18M | -99.04%3.06M | -166.81%-118.79M | 377.54%319.2M | 159.87%177.8M | -94.98%66.84M |
Cash flow from investment activities | ||||||||||
Dividend received - investment | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --3.4M |
Sale of fixed assets | ---- | 24.91%667K | --751K | 14.59%534K | ---- | -7.36%466K | -91.63%120K | -89.68%503K | -74.43%1.43M | 209.73%4.87M |
Purchase of fixed assets | 45.31%-140K | 83.03%-2.69M | 94.95%-256K | -1.00%-15.84M | 55.19%-5.07M | 60.26%-15.69M | -4,071.59%-11.31M | -962.91%-39.47M | 95.54%-271K | 67.68%-3.71M |
Sale of subsidiaries | -100.00%-1K | ---- | --48.1M | ---14.1M | ---- | ---- | ---- | ---- | ---- | ---- |
Recovery of cash from investments | ---- | --22.71M | ---- | ---- | -98.26%1.84M | 5,671.64%105.62M | 5,817.65%106.28M | -64.24%1.83M | --1.8M | -87.12%5.12M |
Cash on investment | ---- | ---- | ---- | ---- | ---2.49M | -556.30%-3.54M | ---- | 97.76%-540K | ---- | -34.09%-24.06M |
Other items in the investment business | ---6K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Net cash from investment operations | -100.30%-147K | 170.35%20.69M | 951.38%48.6M | -133.86%-29.41M | -106.00%-5.71M | 330.56%86.86M | 3,114.87%95.1M | -161.96%-37.67M | 123.11%2.96M | -101.85%-14.38M |
Net cash before financing | -75.67%17.38M | 144.88%138.32M | 121.01%71.42M | -442.80%-308.22M | -1,334.80%-339.89M | -68.06%89.91M | -113.11%-23.69M | 436.63%281.52M | 158.35%180.76M | -97.51%52.46M |
Cash flow from financing activities | ||||||||||
New borrowing | ---- | ---- | ---- | -6.62%378.24M | 378.85%395.55M | -5.16%405.06M | -75.86%82.61M | -86.15%427.08M | -83.68%342.16M | 0.94%3.08B |
Refund | 94.19%-14.79M | 5.46%-273.91M | 15.26%-254.58M | 56.57%-289.72M | -24.78%-300.42M | 66.26%-667.05M | 80.54%-240.77M | 35.33%-1.98B | 36.27%-1.24B | 41.49%-3.06B |
Pledged bank deposit (increase) decrease | ---- | 19.95%117.96M | 20.45%119.44M | -61.30%98.34M | -39.52%99.17M | -74.68%254.1M | -76.07%163.96M | 380.88%1B | 632.59%685.22M | -6.91%-357.36M |
Other items of the financing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 101.99%2.27M |
Net cash from financing operations | 80.56%-27.27M | -209.95%-182.71M | -174.95%-140.26M | 611.67%166.18M | 9,736.30%187.14M | 94.42%-32.48M | 99.16%-1.94M | -57.62%-582.53M | -1,691.87%-230.44M | 85.88%-369.57M |
Effect of rate | -54.57%1.73M | 170.88%15.22M | -85.15%3.81M | -179.19%-21.47M | 169.19%25.66M | 25.19%27.11M | 154.62%9.53M | 237.18%21.66M | -597.48%-17.45M | 76.46%-15.79M |
Net Cash | 85.64%-9.89M | 68.75%-44.39M | 54.94%-68.84M | -347.31%-142.04M | -495.97%-152.75M | 119.08%57.44M | 48.41%-25.63M | 5.08%-301.01M | 83.18%-49.68M | 37.81%-317.11M |
Begining period cash | -19.21%122.67M | -51.85%151.83M | -51.85%151.83M | 36.63%315.35M | 36.63%315.35M | -54.76%230.8M | -54.76%230.8M | -39.49%510.15M | -39.49%510.15M | -40.63%843.05M |
Cash at the end | 31.91%114.51M | -19.21%122.67M | -53.89%86.81M | -51.85%151.83M | -12.32%188.26M | 36.63%315.35M | -51.54%214.7M | -54.76%230.8M | -18.75%443.02M | -39.49%510.15M |
Cash balance analysis | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion |
Auditor | -- | -- | -- | -- | -- | -- | -- | -- | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.